Polyestradiol phosphate

Chemical name

(17бета)-Эстра-1,3,5(10)три��н-3,17-диола polymer broadcast with phosphoric acid

Gross

(C18-H22) m (O4-P) n

Characteristics

Rat in the water.

Of drugs

The drugs-protivoopujolevoe, mode. Associated with estrogenovmi kletok-mishenei receptor. After the / m to the hydrolyses, releasing estradiol, which provides long-term maintenance of its high concentration in the plasma. Is estrogen properties. Effects on гипоталамо-гипофизар��ую system on the feedback reduces testosterone products at 80-90% of the base.

Indications

Cancer prostate cancer (palliative therapy in far coming stages). The women estrogennaya insufficiency (menopausal syndrome, etc.).

Restrictions on the use of

Chronic cardiac and renal failure, arterial hypertension, epilepsy, migraine, porphyria, and the cerebral circulation, heart.

Contraindications

Hypersensitivity expressed by the human liver, tromboamboliceski syndrome, active throm, prolonged immobilization, 12:00 syndrome - Johnson, hereditary pigment gepatozy, sickle cell anemia, fell syndrome. For women, pregnancy, breast-feeding (should stop breastfeeding), menorragii unspecified genesis, estrogenzawisimae tumours, endometriosis, ill indicate jeltukhu and otoscleros, developed during pregnancy.

Side-Effects

Nausea, vomiting, headache, reduced mental performance, depression, tromboembolia Arterial Hypertension whose sodium and water, ginekomastia, reduced libido, impotence in men, allergic reactions (skin rashes, bronchoobstructive syndrome, anaphylactic shock).

Specific guidance

The planned operational interference associated with increased risk of thromboembolism, treatment should stop for six weeks before the operation. Cancel treatment needed when prolonged immobilization, you migrenepodobnykh headaches, sudden violation of the (suspicion of pulmonary veins retina), the trombophlebitis or embolism, cholestatic hepatitis, the AD.

Precautions

A systematic monitoring AD functional status liver, in patients with diabetes-Election profile.

Dosing and Administration

B / m (deep), every 4 weeks. When cancer prostate single dose of 160-320 mg.

Directory → Antineoplastic funds → Antineoplastic hormonal and hormone antagonists → Polyestradiol phosphate